Maganin Kwayoyin Halitta na NS7CAR-T Ya Nuna Alkawari Kan Maganin R/R T-ALL/LBL

Wani littafi da aka buga kwanan nan a cikin mujallar Blood ya jawo hankali sosai ga yuwuwar maganin ƙwayoyin NS7CAR-T don magance cutar sankarar jini mai saurin kamuwa da cutar T-cell lymphoblastic leukemia (R/R T-ALL) da kuma cutar sankarar lymphoblastic ta T-cell (R/R T-LBL). Binciken, wanda aka gudanar a matsayin gwaji na asibiti na mataki na 1 (ClinicalTrials.gov: NCT04572308), ya kimanta aminci da ingancin wannan maganin da aka ƙirƙira.

Gwajin ya haɗa da marasa lafiya da ke ɗauke da R/R T-ALL/LBL waɗanda aka ba su ƙwayoyin NS7CAR-T. Sakamakon ya nuna cewa maganin NS7CAR-T ba wai kawai yana da aminci ba ne, har ma yana nuna kyakkyawan aikin hana ƙari. Marasa lafiya da aka yi wa magani da ƙwayoyin NS7CAR-T sun nuna muhimman amsoshi na asibiti, wanda ke nuna cewa wannan maganin yana da ƙarfi a matsayin kayan aiki mai ƙarfi a kan waɗannan cututtukan daji masu ƙalubale.

Masu binciken da suka gudanar da binciken sun haɗa da ƙungiyar ƙwararru daga Asibitin Hebei Yanda Lu Daopei da Hebei Senlang Biotechnology Co., Ltd. Bincikensu ya nuna cewa ana iya samar da ƙwayoyin NS7CAR-T yadda ya kamata ba tare da ƙarin gyare-gyare na kwayoyin halitta ba don hana bayyanar CD7, yana sauƙaƙa tsarin samarwa da kuma inganta amfani da maganin.

Wannan ci gaba a fannin maganin ƙwayoyin NS7CAR-T ya yi daidai da ci gaba da ƙoƙarin da ake yi na haɓaka magunguna masu inganci ga T-ALL da T-LBL. Kamfaninmu kuma yana ci gaba a wannan fanni tare da mallakarmu. Samfurin CAR-T, wanda muka yi imanin zai ƙara wa sakamakon da aka samu mai kyau da aka lura da shi ta hanyar maganin NS7CAR-T.

Sakamakon ƙarfafa gwiwa na wannan binciken ya buɗe hanya don ƙarin bincike da gwaje-gwaje na asibiti don ƙarfafa rawar da ƙwayoyin NS7CAR-T ke takawa wajen magance cututtukan T-cell da suka sake dawowa ko suka yi tsauri. Yayin da ƙarin bayanai ke ƙaruwa, ana fatan wannan maganin zai zama zaɓi na yau da kullun ga marasa lafiya da ke fama da waɗannan cututtukan masu tsanani.